Dr. Sai kumar Samala

🚨BREAKING: The "Cursor for scientific research" just dropped and it runs entirely inside Claude Code. It's called claude-scientific-skills and it gives Claude 140 ready-to-use scientific skills from a single plugin install. No API doc hunting. No library configuration. No duct-taped research pipelines. It's powered by 28+ live scientific databases wired directly into Claude. → Describe your research goal in plain English → Claude finds the right skill automatically → Full pipeline runs: data retrieval → analysis → publication-ready output → Works across biology, chemistry, medicine, ML, and clinical research All running inside Claude Code. Zero manual setup. But it's not just a prompt library. It's a full AI research lab: → Drug discovery: ChEMBL → RDKit → DiffDock → lead optimization in one prompt → Genomics: 10X data → Scanpy → GRN inference → pathway enrichment → Clinical: VCF → ClinVar → pharmacogenomics → patient report → Multi-omics: RNA-seq + proteomics + metabolomics integrated automatically 7.8k stars. 924 forks. MIT Licensed. MacOS, Windows, Linux works everywhere Claude Code runs. This is the moment AI stops being a chat tool and becomes an actual research partner. Link in the first comment 👇

Grateful to present an oral abstract at #ACRO2026 on DDR1 inhibition + radiation therapy as a novel strategy for pancreatic cancer. . Thanks to mentors, collaborators, and @ACROradonc for an excellent meeting. #ACRO2026

👏 Outstanding talk by @ldawsonmd, our HCC 👸🏻 Clear 💪 story of how EBRT meaningfully integrates into pt care for HCC across all BCLC stages, but esp. in tumors with MVI 🙏🏻 enroll in GI012 @NRGonc to help us answer the❓IO +/- SBRT in unresectable HCC @ACRORadOnc #ACRO2026

Moments like these where a team goes "why don't we just do that?" define history. This particular moment i believe would be one of the most important contributions from the tech world to biomedical science.

Today in Cell, we published new research showing how AI can help accelerate cancer discovery. With GigaTIME, we can now simulate spatial proteomics from routine pathology slides, enabling population-scale analysis of tumor microenvironments across dozens of cancer types and hundreds of subtypes. Developed in partnership with Providence and the University of Washington, our hope is that this work helps scientists move faster from data to insight, revealing new links between genetic mutations, immune activity, and clinical outcomes, and ultimately improving health for people everywhere.

‼️ The treatment is doomed to failed before even prescribed. Stop hoping for lucky mutations. The core problem is pre-existing, established resistance lurking in the tumor right now. Luria-Delbrück explains why 90% kill rates = “CR”, but failure! 🧵

Excited to share our latest review in Cancers! 📝 We took a deep dive into the Unfolded Protein Response (#UPR) —Novel Mechanisms, Challenges, and Key Considerations for Therapeutic Intervention mdpi.com/3586896 #mdpicancers via @Cancers_MDPI

The paper also highlights the need to understand the complex cellular biology post-SBRT. Each tumor type and each tumor is different. It's not just about BED, α/β; clearly,the implications are far more than that.

What it's all about. 💜🥹 Prof. Joel Mokyr, winner of the @NobelPrize in Economic Sciences, shares a lovely message from a former student.

@JoeChangMD This is inspiring work. Hopefully we will see more positive outcomes in IO +SABR trials with this personalized approach in the future.

Who needs immunotherapy after SABR for early-stage NSCLC, and who does not? Our clinical and radiomic AI modeling indicates that only 65% require immunotherapy in this setting. Biologically guided, individualized immunotherapy is the future. urldefense.com/v3/__https:/ji…$

Had an incredible time at #ASTRO2025 in San Francisco! Theme: “Rediscovering Radiation Medicine and Exploring New Indications” -inspiring discussions on innovation and the evolving horizons of #radonc.Honored to present our poster and connect with brilliant mentors & colleagues.

San Francisco's BART might be confusing, especially if you're here for the first time. But BART (Bladder Adjuvant Radiation Therapy) from @VedangMurthy isn't, and it just works. As always, it's a stellar presentation. #ASTRO25 #radonc

Looking forward to #ASTRO2025! Hoping to connect with peers and mentors, learn from your experiences, and build lasting collaborations. Excited to start meaningful conversations #Radonc

@aiims2738 @MoffittNews Congratulations sir

I’m beyond excited to join Moffitt Cancer Center as an Assistant Member in Radiation Oncology @MoffittNews 🔥 #radonc 🎯 Thrilled to join a world-class team pushing the boundaries of cancer care, research & innovation. Stay tuned—exciting projects (and maybe some paradigm shifts 😉) are on the horizon. 🌟 Always grateful to my new and old mentors at @OhioStateRadOnc @MDAndersonNews @aiims_newdelhi

Our new review is out in Nanomaterials! 🧪 Immunomodulatory Effects of Gold Nanoparticles—how AuNPs shape immune cell function, opportunities in inflammation, and key safety considerations. Read: doi.org/10.3390/nano15… #Nanomedicine #Immunology #AuNPs

I have been using several AI tools in the past two years but this by far has surprised me the most. Still trying to figure out how to integrate this to my workflow but this is promising. #NotebookLM #AI #Oncology notebooklm.google

@jryckman3 Congratulations!!

Thrilled to share that I’ve been promoted to Associate Professor! Endlessly grateful to those who’ve supported me along the way, too many to tag, and more generous than I could ever deserve. I’m looking forward to continuing to grow, learn, and give back in whatever way I can.

We are grateful for the tremendous response to our recent manuscript and want to ensure a precise interpretation of our findings. Our research indicates that local radiation therapy in patients with pre-existing metastases may exert paradoxical effects—reducing the dissemination

@rweichselbaum Precisely! "You can’t hit a target if you don’t know what it is". Truly inspiring work! @rweichselbaum

@SaiKumarSamala_ The thing is if you know, something is bad you can neutralize it most of the proteins that have come up. There are either antibodies or small molecules against.

The title may be a little worrying for radiation oncologists.But honestly this is some great work by @rweichselbaum . I have already started analyzing the seq data from the study and it's exciting.We need to push the boundaries of the field even if it's in an uncomfortable space.